AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386
in combination with either pegylated liposomal doxorubicin or topotecan in subjects with
recurrent ovarian cancer. Up to 100 subjects will be enrolled to receive AMG 386 in
combination with either pegylated liposomal doxorubicin every 4 weeks (cohort A) or topotecan
weekly on days 1, 8, and 15 of a 28 day dosing schedule (cohort B). Subject enrollment and
assignment to either cohort will be based on eligibility and the investigator's discretion.
It is hypothesized that AMG 386, in combination with each of the chemotherapy regimens:
either pegylated liposomal doxorubicin or topotecan will be safe and well tolerated in
subjects with recurrent ovarian cancer.